American Society of Hematology
1900 M Street, NW, Suite 200
Washington
D.C.
20036
United States
Tel: 202-776-0544
Fax: 202-776-0545
Website: http://www.hematology.org/
Email: ash@hematology.org
1232 articles with American Society of Hematology
-
Studies Focus on Optimizing Pediatric Care from Birth to Adulthood
12/12/2022
New research being presented at the 64th American Society of Hematology Annual Meeting and Exposition draws attention to previously overlooked issues in caring for babies and young people and sheds light on opportunities to improve the outlook for children with health challenges.
-
Research Highlights Cutting-Edge New Treatments for Blood Disorders
12/10/2022
New research being presented at the 64th American Society of Hematology Annual Meeting and Exposition focuses on a variety of approaches for several hematologic diseases to improve outcomes and quality care.
-
ASH Announces Institutions Selected for the Innovative Hematology-Focused Fellowship Training Program
6/6/2022
The American Society of Hematology announced the institutions that have been selected for the ASH Hematology-Focused Fellowship Training Program, an innovative initiative to address the critical need to expand the hematology workforce.
-
Win Some, Lose Some: Clinical Trial Updates
12/21/2021
After last week’s avalanche of clinical trial news associated with the American Society of Hematology Annual Meeting, there are far fewer announcements, but some companies are getting their news out ahead of the holidays. -
The 63rd ASH Annual Meeting and Exposition is wrapping up today, with dozens providing updates on clinical trials and preclinical research. Here’s a highlight of just a few of those stories.
-
Takeda will present nine abstracts at the annual ASH meeting, including data for its hemophilia program, as well as announcing a new sickle cell disease program.
-
Studies Highlight Novel Approaches to Screening for and Treating Blood Disorders
12/11/2021
Three studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition throw a spotlight on novel approaches to screening for and treating blood diseases, as well as an unexpected, potential association between a blood abnormality and Alzheimer's disease.
-
New Studies Highlight How Immunotherapies Are Transforming Care for Blood Cancers
12/11/2021
Four studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition point to the transformative role immunotherapies are playing in the treatment of major blood cancers.
-
COVID-19 Takes a Toll on People with Blood Cancers and Disorders
12/11/2021
As the COVID-19 pandemic continues to evolve, five studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition shed light on the persisting burden that COVID-19 has had on people with underlying blood disorders.
-
Research Uncovers Gaps and Opportunities in Acute Leukemia Care Across the Lifespan
12/11/2021
Four studies being presented during the 63rd American Society of Hematology Annual Meeting and Exposition highlight opportunities to better serve the needs of patients who have not fully benefited from recent advances in leukemia care and treatment.
-
US Oncology Research, The US Oncology Network and Ontada Announce Data Presentations Across Areas of Critical Need at 2021 American Society of Hematology Annual Meeting and Exposition
12/9/2021
Investigators from US Oncology Research, The US Oncology Network, and OntadaTM will share results from more than 30 studies exploring areas such as diffuse large B cell lymphoma, non-Hodgkin lymphoma, multiple myeloma and hematological adverse event management in the community oncology setting at the 63rd American Society of Hematology Annual Meeting and Exposition.
-
Synthekine and Bright Peak made announcements on their Series B rounds, while Hawthorne Effect and Owl Peak Labs also secured their funding. Let us take a look.
-
Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U.S. FDA.
-
Organizations Collaborate to Develop International State-of-the-Art Guidelines on the Diagnosis and Management of von Willebrand Disease
1/12/2021
The American Society of Hematology, the International Society on Thrombosis and Haemostasis, National Hemophilia Foundation, and World Federation of Hemophilia have developed joint clinical practice guidelines on the diagnosis and management of von Willebrand Disease, the world's most common inherited bleeding disorder.
-
CTI BioPharma Announces Presentation of Data Supporting Pacritinib's Potential Benefit in Preventing Acute GVHD at the 62nd American Society of Hematology Meeting
12/6/2020
Results from Investigator-sponsored Phase 1/2 Study of Acute GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplantation Demonstrate Encouraging Efficacy and Safety Profile when Combining Pacritinib 100 mg BID with Standard Immunosuppressive Therapy
-
ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH Meeting
12/6/2020
Adoptive immunotherapy under investigation for children and adults with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation
-
Durable Clinical Benefits Induced by IMV’s T Cell Therapy in Combination With Merck’s Keytruda in Subjects With PD-L1 Positive r/r DLBCL Presented at ASH Annual Meeting
12/6/2020
PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of 86 % associated with long duration of clinical benefits
-
CARsgen Therapeutics Presents Updated Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition
12/6/2020
CARsgen Therapeutics, a clinical-stage biopharmaceutical company, announced updated safety and efficacy results from its ongoing global clinical studies of CT053, an investigational chimeric antigen receptor T-cell therapy for patients with relapsed and/or refractory multiple myeloma.
-
CALQUENCE Shows Long-Term Efficacy and Tolerability at Three Years for Patients With Relapsed or Refractory Mantle Cell Lymphoma
12/6/2020
ACE-LY-004 Phase II trial results substantiate established efficacy and safety profile of CALQUENCE in mantle cell lymphoma
-
Genome Editing and Cellular Therapies Show Promise for Treating Blood Disorders, Cancers
12/5/2020
Researchers test CRISPR in blood disorders and extend CAR-T therapy to benefit more patients